Resumen de Case Study Based on World Invention Patents of Omeprazole, Lansoprazole, Rabeprazole, Esomeprazole and Pantoprazole
Leandra Guimarães de Oliveira, Cheila Gonçalves Mothé, Araken Alves de Lima, Tatiana Carestiato
This work aims to discuss the importance of patenting as an instrument of incentive to technological innovation in the pharmaceutical area and to present a technological monitoring methodology of pharmaceutical patents of OMEPRAZOL and its derivatives. This is done comparing profiles of patent application in the world, ranging from 1979 to 2009, with emphasis on Industrial Property Databases available on the internet (INPI-Br, DERWENT INNOVATION INDEX, ESPACENET, PATENT SCOPE and USPTO). Drug's keywords omeprazole, lansoprazole, rabeprazole, esomeprazole and pantoprazole were used in order to assess the main inventors, applicants, priority patent country, the main International Patent Classification, date of filling (year of filling), countries where the patent was published and category of claims. In order to ensure that the largest number of relevant documents would be found, it was observed that the combination of terms related to omeprazole, like lansoprazole, rabeprazole, esomeprazole and pantoprazole was important, as well as the intersection with the International Patent Classifications (IPC A61K 31/3349, C07D 401/12 and A61P 1/04). Related to patents of omeprazole and its derivatives in the world, data showed the main applicant was the company Astrazeneca AB (129 applications); the main inventor was Wolfgang-Alexander Simon with his name cited in 41 applications; the largest number of patent applications comes from USA (186 applications), pointing to the American hegemony in this area; and the category of claim most frequently claimed was composition (602 results).
